Menu
Search
|

Menu

Close
X

PLx Pharma Inc PLXP.OQ (NASDAQ Stock Exchange Capital Market)

4.00 USD
+0.05 (+1.27%)
As of Jul 16
chart
Previous Close 3.95
Open 4.00
Volume 1,007
3m Avg Volume 2,111
Today’s High 4.00
Today’s Low 4.00
52 Week High 9.40
52 Week Low 3.20
Shares Outstanding (mil) 8.69
Market Capitalization (mil) 55.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
0
FY15
0
EPS (USD)
FY18
0.571
FY17
-1.760
FY16
-0.851
FY15
-15.852
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
146.75
5.73
Price to Book (MRQ)
vs sector
3.75
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-54.02
14.61
Return on Equity (TTM)
vs sector
-75.17
16.34

EXECUTIVE LEADERSHIP

Rita O'Connor
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Robert Shawah
Chief Accounting Officer, Treasurer, Since 2014
Salary: $138,751.00
Bonus: --
Steven Valentino
Vice President - Trade Sales, Since 2017
Salary: --
Bonus: --
Tom Long
Vice President - Manufacturing & Technical Operations, Since 2017
Salary: --
Bonus: --
Gary Balkema
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8285 El Rio St Ste 130
HOUSTON   TX   77054-4654

Phone: +1713.8421249

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

SPONSORED STORIES